The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|October 18, 2018
5 Questions About Rheumatoid Arthritis: A Quiz
Five questions to test your knowledge of the prevalence, risk, and classification of RA.
Advertisement
How much do you know about the prevalence, risk, and classification of rheumatoid arthritis (RA)? Start below with the first of 5 questions to find out.
Question 1.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement